Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC.CSBR · Entity 7013 | President | October 09, 2023 | April 01, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHAMPIONS ONCOLOGY, INC.
Report date October 09, 2023 · Filed April 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2033-10-09 | Direct | 135,000 |
Reported balance
After 2023-10-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-10-09 · Grant · Acquired 135,000 · Balance 135,000 F1: The options vest over a four year period and are exercisable over a ten year period, with vesting to occur on October 9, 2024, October 9, 2025, October 9, 2026 and October 9, 2027, respectively. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2033-10-09 | Direct | 142,500 |
Reported balance
After 2023-10-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-10-09 · Grant · Acquired 7,500 · Balance 142,500 F2: The options vest fully (100%) on the one year anniversary of the date of grant and are exercisable over a ten year period, with vesting to occur on October 9, 2024. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2033-10-09 | Direct | 210,500 |
Reported balance
After 2023-10-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-10-09 · Grant · Acquired 68,000 · Balance 210,500 F3: The options vest over a four year period starting from the one year anniversary of the achievement of specific performance criteria and are exercisable over a ten year period. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest over a four year period and are exercisable over a ten year period, with vesting to occur on October 9, 2024, October 9, 2025, October 9, 2026 and October 9, 2027, respectively.
F2: The options vest fully (100%) on the one year anniversary of the date of grant and are exercisable over a ten year period, with vesting to occur on October 9, 2024.
F3: The options vest over a four year period starting from the one year anniversary of the achievement of specific performance criteria and are exercisable over a ten year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2023 Filed Apr 1, 2024 19:18 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 68,000 | $6.50 Strike: $6.50 | $442,000.00 |
DisclosureSEC source: 0001628280-24-013993 · wk-form4_1711999092.xml · derivative · entry 3 Davis Brady · CIK 0002002615 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,500 Underlying: Common Stock · 68,000 shares Expires 2033-10-09 F3 · derivative.exercise_date: The options vest over a four year period starting from the one year anniversary of the achievement of specific performance criteria and are exercisable over a ten year period. Read SEC document |
| October 09, 2023 Filed Apr 1, 2024 19:18 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 7,500 | $6.50 Strike: $6.50 | $48,750.00 |
DisclosureSEC source: 0001628280-24-013993 · wk-form4_1711999092.xml · derivative · entry 2 Davis Brady · CIK 0002002615 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,500 Underlying: Common Stock · 7,500 shares Expires 2033-10-09 F2 · derivative.exercise_date: The options vest fully (100%) on the one year anniversary of the date of grant and are exercisable over a ten year period, with vesting to occur on October 9, 2024. Read SEC document |
| October 09, 2023 Filed Apr 1, 2024 19:18 UTC | CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013 | GrantOption to purchase Common Stock · Derivative | 135,000 | $6.50 Strike: $6.50 | $877,500.00 |
DisclosureSEC source: 0001628280-24-013993 · wk-form4_1711999092.xml · derivative · entry 1 Davis Brady · CIK 0002002615 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2033-10-09 F1 · derivative.exercise_date: The options vest over a four year period and are exercisable over a ten year period, with vesting to occur on October 9, 2024, October 9, 2025, October 9, 2026 and October 9, 2027, respectively. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.